Immunotherapy for the management of advanced melanoma: The next steps

Dragoslav Zikich, Jacob Schachter, Michal J. Besser*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review


Melanoma is an immunogenic tumor that can induce a natural immune response. A number of immunotherapy-based approaches have been developed over the past decades, and certain degrees of effectiveness were achieved by the use of cytokines, adoptive cell transfer and T-cell immune modulators. Currently, interleukin-2 and the immune stimulatory antibody, ipilimumab, are the only two approved immunotherapies for metastatic melanoma, but various new therapies are in promising developmental stages. This comprehensive review will discuss the latest achievements of immunotherapy and emerging directions for the management of advanced melanoma.

Original languageEnglish
Pages (from-to)261-272
Number of pages12
JournalAmerican Journal of Clinical Dermatology
Issue number4
StatePublished - Aug 2013


Dive into the research topics of 'Immunotherapy for the management of advanced melanoma: The next steps'. Together they form a unique fingerprint.

Cite this